Proteomics International Laboratories (ASX:PIQ) has appointed David Morris as CEO and Managing Director, effective Jan. 19.
Morris, a seasoned global healthcare and medical technology executive, brings extensive experience across medical devices and life sciences, including leadership roles at Cochlear, Nanosonics, Polynovo, and Monash IVF.
He is recognised for driving commercial growth, international market expansion, product commercialisation, and high-performing teams.
His appointment aligns with Proteomics International’s intensified focus on commercialising its Promarker diagnostic pipeline and expanding its global footprint.
Morris succeeds Dr Richard Lipscombe, the company's founder and outgoing Managing Director, who will retire on Feb. 23 after 25 years of leadership and will support a transition period.
Proteomics International Chair Dr James Williams said Morris' commercial expertise and proven track record make him "exceptionally well placed to lead the next phase of growth," while also thanking Dr Lipscombe for his instrumental role in establishing the company as a global leader in precision diagnostics.
At the time of reporting, Proteomics International Laboratories' share price was $0.82.